Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20974482 | 0.89 | TOP2A (0.40) | — | |
| SCHEMBL4729467 | 0.87 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL1566423 | 0.86 | RNASE1 (0.48) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7221864 | 0.86 | RNASE1 (0.48) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2122161 | 0.86 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2611630 | 0.86 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2122164 | 0.86 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL15061820 | 0.86 | RNASE1 (0.44) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL23620675 | 0.85 | LMNA (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL20810838 | 0.85 | RNASE1 (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195493-B2 | Reversibly blocked nucleoside analogues and their use | MGI TECH CO., LTD. (CN) | 2025-01-14 | — | — | US | disclosed |
| CN-109790196-B | Reversibly blocked nucleoside analogs and uses thereof | 深圳华大智造科技股份有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20210206794-A1 | REVERSIBLY BLOCKED NUCLEOSIDE ANALOGUES AND THEIR USE | MGI TECH CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-20210206794-A1 | REVERSIBLY BLOCKED NUCLEOSIDE ANALOGUES AND THEIR USE | MGI TECH CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-10988501-B2 | Reversibly blocked nucleoside analogues and their use | MGI TECH CO., LTD. | 2021-04-27 | — | — | US | disclosed |
| US-10988501-B2 | Reversibly blocked nucleoside analogues and their use | MGI TECH CO., LTD. | 2021-04-27 | — | — | US | disclosed |
| US-20190144482-A1 | Reversibly Blocked Nucleoside Analogues And Their Use | MGI TECH CO., LTD. (CN) | 2019-05-16 | — | — | US | disclosed |
| US-20190144482-A1 | Reversibly Blocked Nucleoside Analogues And Their Use | MGI TECH CO., LTD. (CN) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144482-A1 | Reversibly Blocked Nucleoside Analogues And Their Use | NSUN2, NME2, ADAR | RNASE1 69/4885LMNA 589/4885SMN1; SMN2 883/4885 |
| US-20210206794-A1 | REVERSIBLY BLOCKED NUCLEOSIDE ANALOGUES AND THEIR USE | NSUN2, NME2, ADAR | RNASE1 69/4885LMNA 589/4885SMN1; SMN2 883/4885 |
| US-12195493-B2 | Reversibly blocked nucleoside analogues and their use | NSUN2, NME2, ADAR | RNASE1 69/4885LMNA 589/4885SMN1; SMN2 883/4885 |
| US-10988501-B2 | Reversibly blocked nucleoside analogues and their use | NSUN2, NME2, ADAR | RNASE1 69/4885LMNA 589/4885SMN1; SMN2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.